Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 8/20 | 0.47 |
| ▸ | TGM2 | P21980 | 6/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.36 |
| ▸ | CASP3 | P42574 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14499386 | 0.79 | CES1 (0.46) | CES1TGM2BCHEMAOAMAOB | |
| SCHEMBL3871129 | 0.78 | CES1 (0.37) | CES1ALDH1A1POLBMAPTTDP1 | |
| SCHEMBL4683713 | 0.76 | ALDH1A1 (0.47) | CES1TGM2BCHEALDH1A1L3MBTL1 | |
| SCHEMBL4680850 | 0.73 | CES1 (0.71) | CES1TGM2BCHEMAOAMAOB | |
| SCHEMBL14584631 | 0.73 | CES1 (0.58) | CES1TGM2BCHEMAOAMAOB | |
| SCHEMBL14221459 | 0.72 | CES1 (0.39) | CES1TGM2BCHEMAOAMAOB | |
| SCHEMBL3726368 | 0.69 | CES1 (0.41) | CES1TGM2 | |
| SCHEMBL31381684 | 0.69 | CES1 (0.41) | CES1TGM2 | |
| SCHEMBL4679100 | 0.68 | CES1 (0.55) | CES1TGM2MAOAMAOB | |
| SCHEMBL2372316 | 0.68 | CES1 (0.58) | CES1TGM2MAOAMAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1333834-B1 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20070135464-A1 | Antiinflammation agents | AMGEN, INC. | 2007-06-14 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186841-B2 | (2-imidazolyl)quinolin-4-yl aldehydes; immunomodulators, antiproliferative agents; metabolic disorders | AMGEN INC. (US) | 2007-03-06 | — | — | US | disclosed |
| EP-1333834-A4 | ANTIINFLAMMATION AGENTS | AMGEN INC (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20050043330-A1 | Antiinflammation agents | AMGEN INC. (US) | 2005-02-24 | — | — | US | disclosed |
| US-6846834-B2 | Compounds contain fused carbocyclic or heterocyclic rings; modulate expression and/or function of proteins involved in inflammation, metabolism and cell proliferation | AMGEN INC. (US) | 2005-01-25 | — | — | US | disclosed |
| CN-1503673-A | Anti-inflammatory agent | �㽭�пؼ����ɷ�����˾ | 2004-06-09 | — | — | CN | disclosed |
| EP-1333834-A2 | ANTIINFLAMMATION AGENTS | Tularik Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-20020161004-A1 | Antiinflammation agents | SYNTEX (U.S.A.) LLC (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002041843-A2 | ANTIINFLAMMATION AGENTS | TULARIK INC. (US) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135464-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CES1 813/4885TGM2 722/4885BCHE 2588/4885 |
| US-20050043330-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CES1 813/4885TGM2 722/4885BCHE 2588/4885 |
| US-20020161004-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CES1 813/4885TGM2 722/4885BCHE 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.